Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Large Decrease in Short Interest

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totaling 6,607 shares, a drop of 50.9% from the August 31st total of 13,469 shares. Based on an average daily trading volume, of 43,279 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.6% of the company’s stock are sold short.

Institutional Trading of Regentis Biomaterials

An institutional investor recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new stake in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned 5.79% of Regentis Biomaterials as of its most recent filing with the Securities & Exchange Commission.

Regentis Biomaterials Trading Up 0.8%

NYSEAMERICAN:RGNT traded up $0.01 during midday trading on Thursday, reaching $1.82. 6,940 shares of the company traded hands, compared to its average volume of 1,849,370. The company has a fifty day moving average price of $1.96 and a 200 day moving average price of $2.61. Regentis Biomaterials has a twelve month low of $1.23 and a twelve month high of $15.50.

Regentis Biomaterials (NYSEAMERICAN:RGNT) last announced its earnings results on Friday, September 11th. The company reported ($0.22) EPS for the quarter.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is an Israel-based medical device company developing biomaterial technologies for the treatment of cartilage injuries and other orthopedic conditions. The company focuses on regenerative solutions intended to support the repair of damaged tissue while reducing the need for more invasive procedures.

Its lead product is GelrinC, a synthetic, cell-free hydrogel implant designed for the treatment of focal cartilage defects in the knee. The product is placed arthroscopically and forms a scaffold intended to integrate with surrounding tissue and support the regeneration of hyaline-like cartilage.

Regentis Biomaterials operates as a clinical-stage company, with activities centered on product development, clinical evaluation, regulatory advancement and potential commercialization of its orthopedic biomaterial platform.